Ivosidenib is an oral selective reversible inhibitor of the mutant form of the IDH1 enzyme that is associated with a wide range of cancers, including approximately 6–9% of AML cases. Mutant IDH1 is linked to the over-production of the metabolite D-2-hydroxygluterate, which inhibits cellular differentiation and can lead to the transformation of cancerous cells.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.